Beditine, a new benzodioxane derivative, as a suppressor of human polymorphonuclear leukocyte and platelet activation.
Beditine, 2-(2-amino-4-thiazolyl)-1,4-benzodioxane hydrochloride is a new substance which reduced platelet activation and degranulation, prevented aggregation and superoxide generation by activated human polymorphonuclear leukocytes (PMNL) and inhibited the activation of arachidonate 5-lipoxygenase. Beditine may, therefore, be a useful agent in the treatment of cardiovascular disease.
Panossian
A
A
C. Guelbenkian Research Laboratories of the Drug Agency of the Ministry of Health, Yerevan, Armenia. phanos@drag.iiap.sci.am
Grigorian
G
G
Akopov
S
S
Aivasian
A
A
Markarian
E
E
Vartanian
S
S
Gabrielian
E
E
D000255:Adenosine Triphosphate / Q000378:metabolism; D001241:Aspirin / Q000494:pharmacology; D000001:Calcimycin; D004146:Dioxanes / Q000494:pharmacology*; D015777:Eicosanoids / Q000096:biosynthesis; D006801:Humans; D016859:Lipoxygenase Inhibitors; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D009543:Nifedipine / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D013844:Thiazoles / Q000494:pharmacology*
D004146:Dioxanes; D015777:Eicosanoids; D016859:Lipoxygenase Inhibitors; D010975:Platelet Aggregation Inhibitors; D013844:Thiazoles; C107649:beditine; D013481:Superoxides; D000001:Calcimycin; D000255:Adenosine Triphosphate; D009543:Nifedipine; D001241:Aspirin